{"ticker": {"uuid": "cbaf0ba4-9a5f-4624-83a0-ceb9d0edb90e", "symbol": "CMPS", "name": "Compass Pathways\u00a0Plc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Care Facilities"}, "articles": [{"title": "Should COMP360\u2019s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T18:42:53+00:00", "published_display": "15 Jul 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is COMPASS Pathways plc (CMPS) Stock a Psychedelic Medicine Opportunity After Positive COMP360 Data?", "summary": "COMPASS Pathways plc (CMPS) is being considered a strong psychedelic medicine opportunity after positive 26-week results from its Phase 3 COMP006 study for COMP360, a treatment for resistant depression. Oppenheimer reaffirmed its Outperform rating and $20 price target, highlighti", "url": "https://uk.finance.yahoo.com/news/compass-pathways-plc-cmps-stock-092249577.html", "source_name": "Market source", "published_at": "2026-07-15T09:22:00", "published_display": "15 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dow, Nasdaq, S&P 500 Futures Climb Amid US-Iran Tensions, Fed Inflation Worries: WULF, CMPS, ANET, PENG Stocks In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQZ2o5d2J4V3JjNEpRWTVPcl90YTV3XzRleXhSYTlHS2c5NmlOelk0VnF0NDZ5R3JOQmxteEpoZEVMTzVMdVltbEg2d2xQQjAzQWNPM3kwM1I5UkhNaE9TTlpQdEVCaUIyeUV1NllTMUdHc1VWZThDZ05RSTJEeWl6aXZENUhEay1IX0FWMWxNQUNuS3pWRUgzcUQ2bjZ5b05oZHRpejJLYl9ESVdtQzc5dVlSN0Rzc3VZaHpFMWVtLVZ6bWZ4c2J4MDZJVjRlQTdXTXFhaQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T05:44:12+00:00", "published_display": "13 Jul 2026 05:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up", "summary": "", "url": "https://finance.yahoo.com/m/5ebcd5f3-d59e-32ed-a179-ee8a11921994/compass-pathways-eyes-2027.html", "source_name": "MarketBeat", "published_at": "2026-07-10T07:02:09+00:00", "published_display": "10 Jul 2026 07:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPASS Pathways (CMPS) Gets A Fresh Valuation Test On New Phase 3 Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPQXp2dy1XeE84WVJvLTlhVnJBZldGaG1jdnNpUVJ3UU00dmdrNlBKbTk5Wl93dFBKMjNZUjZaU1ZfREs0WEdUVjNmekttbUdMZ2RWaFdfd3VfekVoZWxnMlB0NDRCZ0dqX2NSYTU1ZlZrNUY3T04zUXdzSG55akdXbTVUb1RxeE1VTXZMT01vYjBJQ1lsSFM2MDZFczl0eE8zc0YzdGlDYUFVaGFSRzRpRlJFeFJFQmVidmtmbm9fTW8xNDlxbFU0YjRWSUhoMVRnY2JHNUt5Y0V4ZGxFYkZ3U3hqNF_SAeoBQVVfeXFMT0xMRkxoNFdyaElQMnl5OVpaNnltUmwtN0tHZHRsRmZkU3ZoaVNwc19oaGdBZlFaSE1KZjdqNkFGMnEzYzRoWGxpX1FXcTJPLVM0LUpabVhZOWF2bDhoczdmQmdsenVnRHdnVVNGa0gtVXV3Q2Rfb2Z3YnFnS251RWVRUHJxWDZXVVVRUEV5elVWRUpfLWZZZEpVbmhtM2lrUS1RaTZMVkxlMkgyVnJNYWkzRzc3eENFZUwxcVNnYkI1UFNpby1wdkZqZDFwV1NjSERvYkhaWm04aFZDOXV6V2ZFVnV4bHlZS0NB?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T10:35:42+00:00", "published_display": "09 Jul 2026 10:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does COMPASS Pathways (CMPS) Have Upside Left Above Fair Value?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQQjBmQUJkaGNFdFhNLWNfbUJkczJvVGp5eUhrYlE0Y3VUQjhzWkdJT25KMUJPUjUyX2NNdTlZU3hZelpDLTFxRDRuUjBnZHB5b3RXLTNORnE2SU93QkhZZXh5eVBaSDBBaVh0WVktWkxNbjEzd1FESkpCQ3Y0MURVYU92blBndzVfWFJHcnBvcFFTc3A3NTRnc3ZBRTFnOFk?oc=5", "source_name": "Market source", "published_at": "2026-07-09T02:12:00+00:00", "published_display": "09 Jul 2026 02:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOdkZXUnVmcl9lb3hlbS1DMm1vUEItNVhFbHhzclRaUUItOGFVWVNlQmdiSE81aW1IVWpmVVVuVzhWT0JvbS1VdWRWRkNhQlYxcUVQRzRTQ01pT3pjYTBienJUOVFUME5fcnhwSGdZaGJsampuNlgwLVdxZWxFcTlzZnRSNHZDSGJiR2VqYVk1ZXRuSUpvT1hwZEVwSEVkRnRqcjNIT0xjVk9nMi1LU1RjNGVZbVdaS0FFNGZhMUFvNXZPeGJFYlNWVGlQTVRBZlU?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-09T01:30:39+00:00", "published_display": "09 Jul 2026 01:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock upgraded at Evercore ISI (CMPS:NASDAQ)", "summary": "Evercore ISI has upgraded Compass Pathways (CMPS) to Outperform from Inline and significantly increased its price target to $21 from $8. This upgrade follows the release of updated late-stage trial results showcasing the long-term efficacy of the U.K.-based biotech's psychedelic ", "url": "https://seekingalpha.com/news/4612334-compass-pathways-stock-upgraded-evercore-isi", "source_name": "Seeking Alpha", "published_at": "2026-07-08T16:40:08", "published_display": "08 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of COMPASS Pathways Plc - American Depository Shares \u2013 NASDAQ:CMPS", "summary": "This page from TradingView displays the \"Price to book forward\" metric for COMPASS Pathways Plc - American Depository Shares (NASDAQ: CMPS). It indicates the stock's financial overview, specifically its price-to-book ratio on a forward-looking basis. The content provides basic co", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T03:06:12", "published_display": "08 Jul 2026 03:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways Reports Six-Month Data from Second Phase 3 Trial of Comp360 for Treatment-Resistant Depression", "summary": "Compass Pathways announced positive 26-week data from its second Phase 3 COMP006 trial for COMP360 psilocybin in treatment-resistant depression (TRD), confirming its rapid onset and durable profile. The findings, building on previous trial results, showed that 39% of patients in ", "url": "https://www.marketscreener.com/news/compass-pathways-reports-six-month-data-from-second-phase-3-trial-of-comp360-for-treatment-resistant-ce7f5ed8d88bf023", "source_name": "www.marketscreener.com", "published_at": "2026-07-08T01:40:09", "published_display": "08 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass\u2019 psilocybin shows six-month durability in Phase III trial", "summary": "Compass Pathways' psilocybin-based therapy, COMP360, has demonstrated six-month durability in a Phase III trial for treatment-resistant depression (TRD), building on earlier six-week data. The therapy showed rapid onset and sustained response, with a generally well-tolerated safe", "url": "https://www.clinicaltrialsarena.com/news/compass-psilocybin-shows-six-month-durability-in-phase-iii-trial/", "source_name": "Clinical Trials Arena", "published_at": "2026-07-08T01:39:46", "published_display": "08 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why COMPASS Pathways (CMPS) Is Down 8.2% After New Phase 3 Data and Rolling NDA Update", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T00:07:01+00:00", "published_display": "08 Jul 2026 00:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why This Psychedelics Stock Reversed Its Bearish Fortunes", "summary": "Compass Pathways (CMPS) stock saw a significant turnaround after announcing positive clinical trial results for its psilocybin-based treatment for depression. The treatment showed clinically meaningful improvements in 39% of patients after two fixed doses, with durable results la", "url": "https://www.investors.com/news/technology/compass-pathways-stock-psychedelic-drug-depression-treatment/", "source_name": "Investor's Business Daily", "published_at": "2026-07-07T20:12:43", "published_display": "07 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMP360 Psilocybin Shows Durable TRD Benefit", "summary": "Compass Pathways has announced 26-week data from its second Phase III trial of COMP360, a synthetic psilocybin formulation for treatment-resistant depression (TRD). The results indicate that antidepressant effects observed at six weeks were maintained through six months, strength", "url": "https://allsci.com/news/clinical-trials/compass-pathways-comp360-becomes-first-classic-psychedelic-to-prove-durable-six-month-benefit-in-trd/", "source_name": "AllSci", "published_at": "2026-07-07T18:11:35", "published_display": "07 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies reiterates Compass Pathways stock rating on trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOcGJmckNFUGh2LXhCTjFyZzJUVV9wWmxqLWVfVU9ESW0tcVdjanFqQXp1dGpzLWNWTUp3LS1raVYwOHBvQ05jU1ZRMFdINi1PM0ZuM0laSWFZU3U2bFVaSGxoTmtZbjBXeXJPNS1ndlNNR1ZGM1JQS2t2LXRfMFRQbjdBaVdWem5qclZhRTlsTGNoUmV1Y2VFTlRPUWJMbjA5MnNRWHlUdDNnaWFncEFEcThNeExRbmFEdGIzVjZFMmtpUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-07T15:21:25+00:00", "published_display": "07 Jul 2026 15:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile", "summary": "Compass Pathways has announced positive six-month data from its second Phase 3 trial (COMP006) for COMP360, a psilocybin treatment for treatment-resistant depression (TRD). The results reinforce the rapid onset and durable effectiveness of COMP360, showing sustained benefit up to", "url": "https://investingnews.com/compass-pathways-announces-six-month-data-from-second-phase-3-trial-confirming-rapid-and-durable-profile/", "source_name": "Investing News Network", "published_at": "2026-07-07T13:12:43", "published_display": "07 Jul 2026 13:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways Releases New Data on COMP360 for Treatment-Resistant Depression", "summary": "Compass Pathways has released new data from its Phase 3 COMP006 trial for COMP360, a treatment for resistant depression, showing rapid onset and durable clinical effects. The therapy also maintains a strong safety profile and is on track for a rolling FDA new drug application sub", "url": "https://intellectia.ai/news/stock/compass-pathways-releases-new-data-on-comp360-for-treatmentresistant-depression", "source_name": "Intellectia AI", "published_at": "2026-07-07T12:20:07", "published_display": "07 Jul 2026 12:20", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass gains on new late-stage trial data for psychedelic therapy in depression", "summary": "Compass Pathways (CMPS) saw an ~8% rise in early premarket trading after releasing new 26-week data from Part B of an ongoing late-stage trial for its psychedelic therapy, COMP360. The trial is evaluating COMP360 as a treatment for resistant depression. This positive data follows", "url": "https://seekingalpha.com/news/4611891-compass-posts-trial-data-psychedelic-drug", "source_name": "Seeking Alpha", "published_at": "2026-07-07T11:42:07", "published_display": "07 Jul 2026 11:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways says second psilocybin trial kept depression benefit for 6 months", "summary": "Compass Pathways announced 26-week results from its second Phase 3 trial (COMP006) for COMP360, a synthetic psilocybin formulation for treatment-resistant depression (TRD), confirming rapid onset and durable benefit for at least six months. This data, consistent with previous tri", "url": "https://www.stocktitan.net/news/CMPS/compass-pathways-announces-six-month-data-from-second-phase-3-trial-jkjn16eqsxqs.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:42:07", "published_display": "07 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phase 3 TRD results move Compass (NASDAQ: CMPS) toward COMP360 NDA", "summary": "Compass Pathways has reported positive 26-week data from its Phase 3 COMP006 trial for COMP360 psilocybin treatment in treatment-resistant depression (TRD), showing durable efficacy and a well-tolerated safety profile. The company is proceeding with a rolling NDA submission to th", "url": "https://www.stocktitan.net/sec-filings/CMPS/8-k-compass-pathways-plc-reports-material-event-23ad7b8f3b99.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:42:07", "published_display": "07 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways reports 6-month data from phase 3 TRD trial", "summary": "Compass Pathways announced that its COMP006 Phase 3 trial for COMP360 psilocybin in treatment-resistant depression (TRD) showed durable benefits over 26 weeks, with 39% of participants achieving significant reduction in depression scores. The company plans a rolling New Drug Appl", "url": "https://www.investing.com/news/company-news/compass-pathways-reports-6month-data-from-phase-3-trd-trial-93CH-4778700", "source_name": "Investing.com", "published_at": "2026-07-07T10:42:07", "published_display": "07 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways: COMP360 shows rapid onset, durable 26-week benefit in Phase 3 COMP006; rolling NDA on track for Q4", "summary": "Compass Pathways reported positive 26-week results for its COMP360 treatment in treatment-resistant depression from the Phase 3 COMP006 trial, showing rapid onset and durable clinical benefits. A rolling NDA submission is progressing as planned for completion in Q4 2026. The comp", "url": "https://www.tradingview.com/news/tradingview:ce91340e16419:0-compass-pathways-comp360-shows-rapid-onset-durable-26-week-benefit-in-phase-3-comp006-rolling-nda-on-track-for-q4/", "source_name": "TradingView", "published_at": "2026-07-07T10:42:07", "published_display": "07 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Compass Pathways stock gaining today? By Investing.com", "summary": "Compass Pathways Plc (CMPS) stock gained 3.5% in pre-market trading, continuing its recovery from a 52-week low. This surge is driven by anticipation for the company's COMP006 Phase 3 trial durability data, expected in early Q3 2026, and a planned New Drug Application submission ", "url": "https://m.za.investing.com/news/stock-market-news/why-is-compass-pathways-stock-gaining-today-93CH-4356023?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-06T16:40:32", "published_display": "06 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of COMPASS Pathways Plc - American Depository Shares \u2013 NASDAQ:CMPS", "summary": "This article provides price to sales forward data for COMPASS Pathways Plc (NASDAQ: CMPS). It includes the period, value, change, and percentage change. The content highlights financial data sourced from ICE Data Services and FactSet for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T23:12:28", "published_display": "05 Jul 2026 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Compass Pathways plc announced equity awards granted to eight new non-executive employees under its 2026 Inducement Plan. These grants, consisting of options and restricted share units, were made on July 1, 2026, as a material inducement for employment and are in compliance with ", "url": "https://www.businesswire.com/news/home/20260702092582/en/Compass-Pathways-Announces-New-Employee-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4", "source_name": "Business Wire", "published_at": "2026-07-02T10:30:02", "published_display": "02 Jul 2026 10:30", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways gives new hires 63,685 options and RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPbXpuR3JRbDF6WFlWVDNZQ1d0M0ZVcDY3U21oLXN0eXVSVHNjX1dXekZQbzVvdG1mU1ZTQ2EtLXJwR3pzaWxOVjA2Uk9RS1UtcGlqUHlaS2tnZFI3TlpxZG1xZ0ZUXzhfek5vaVRtanZkblBZVFRyM0U0bUhWMDRHOWRLU0tRd1JRcWNteUdjSHdNNnRwZWlHTlFtS0Vram14Z1NBWnNDbnZaY09QWEEtR0Z3QmxEQ3NmdkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways Announces FDA Granted NDA Rolling Review Request", "summary": "Compass Pathways announced that the FDA granted its NDA rolling review request for COMP360, their proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD). The company also received a Commissioner's National Priority Voucher (CNPV), which provides", "url": "https://www.natlawreview.com/press-releases/compass-pathways-announces-fda-granted-nda-rolling-review-request-and", "source_name": "The National Law Review", "published_at": "2026-07-01T23:11:46", "published_display": "01 Jul 2026 23:11", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of COMPASS Pathways Plc - American Depository Shares \u2013 NASDAQ:CMPS", "summary": "The article focuses on the enterprise value to EBIT forward metric for COMPASS Pathways Plc (NASDAQ: CMPS). It appears to be a financial data page from TradingView, providing an overview of the company's financial information within the health technology and biotechnology sectors", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPS/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:09:12", "published_display": "30 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of COMPASS Pathways Plc - American Depository Shares \u2013 NASDAQ:CMPS", "summary": "This article provides financial information for COMPASS Pathways Plc (CMPS) listed on the NASDAQ Stock Market, specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or an empty data table from TradingView, indicating that specific financia", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:41:34", "published_display": "29 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock hits 52-week high at 14.77 USD", "summary": "Compass Pathways Plc (CMPS) has hit a new 52-week high of $14.76, reflecting a robust 411% one-year stock performance and a market capitalization of $1.98 billion. This surge is attributed to investor confidence in the psychedelic therapy sector, recent positive Phase 3 data for ", "url": "https://m.uk.investing.com/news/stock-market-news/compass-pathways-stock-hits-52week-high-at-1477-usd-93CH-4746650?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-26T16:10:25", "published_display": "26 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPASS Pathways (CMPS) Receives a Buy from H.C. Wainwright", "summary": "H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on COMPASS Pathways (CMPS) with a price target of $70.00. Trucchio, a 5-star analyst, has a strong track record in the Healthcare sector. The company recently reported a significant net profit of $91.05 million for ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/16053/compass-pathways-cmps-receives-a-buy-from-h-c-wainwright/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T13:10:25", "published_display": "26 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPASS Pathways Plc Sponsored ADR Actuals & Estimates (NASDAQ:CMPS)", "summary": "This article provides an overview of COMPASS Pathways Plc (NASDAQ: CMPS) on TradingView, focusing on its financial actuals and estimates. It highlights reported financial data and analyst estimates across various financial statements and valuation metrics, allowing users to compa", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPS/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-25T23:09:54", "published_display": "25 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways PLC (CMPS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Compass Pathways PLC (CMPS) stock, focusing on its dividend and stock split history. It states that no dividends have been distributed over the past five years and no stock split data is available. The article also includes current stock price", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmps/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T12:40:34", "published_display": "18 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways PLC (CMPS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Compass Pathways PLC (CMPS), including analyst ratings, target prices, and EPS estimates. Based on 16 analysts, the stock has a \"Buy\" rating with an average target price of $21.719, representing an 89.02% upside. The report also high", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmps/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T07:40:34", "published_display": "18 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways PLC (CMPS) Institutional Confidence", "summary": "This article provides an overview of Compass Pathways PLC (CMPS) focusing on its institutional confidence, a component of its TradingKey Stock Score. It details institutional shareholdings and recent activity by significant investors, including changes in their positions. Key ins", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmps/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:34", "published_display": "18 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways IPO to Begin Trading 18th September on Nasdaq: CMPS", "summary": "Compass Pathways has announced that its initial public offering of 7.5 million shares will begin trading on the Nasdaq Global Select Market today, September 18, 2020, under the ticker CMPS. The shares are priced at $17.00, raising gross proceeds of $127.5 million. The offering is", "url": "https://psychedelicalpha.com/news/compass-pathways-ipo-to-begin-trading-18th-september-on-nasdaq-cmps/", "source_name": "Psychedelic Alpha", "published_at": "2026-06-16T03:40:11", "published_display": "16 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is COMPASS Pathways plc (CMPS) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxON3BoZXYtVloyYXVJMHA0amx2TFNJT2JXVU9FS1pIQThER0lqZXFIS0htMTFGUFp5eHc1alc4ZVowOXZLU09hMVNfOUJkajRzWlhud1hZX2dveHJWaEJQSVluXzZBYzhTbXo0SUpTdlZadUdieHdxdTY0TlR4NEhab2NIVVI0cFRlS1ZfLVBXYjkwM0h6ZEl1YWZWdw?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript: Compass Pathways Q1 2026 Earnings Conference Call", "summary": "Compass Pathways reported positive data from its Phase 3 studies of COM360 for treatment-resistant depression (TRD), showing rapid and durable efficacy. The company is preparing for a potential accelerated launch by the end of the year, backed by strong financials, ongoing FDA co", "url": "https://finance.yahoo.com/sectors/healthcare/articles/transcript-compass-pathways-q1-2026-223421373.html", "source_name": "Market source", "published_at": "2026-06-06T12:41:33", "published_display": "06 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPS Stock Chart | COMPASS PATHWAYS PLC (NASDAQ:CMPS)", "summary": "This article provides a stock chart for COMPASS PATHWAYS PLC (NASDAQ:CMPS) on ChartMill.com. It displays the current stock price, daily changes, and after-hours trading information. The page also offers various trading tools and market data for analysis.", "url": "https://www.chartmill.com/stock/quote/CMPS/stock-chart", "source_name": "ChartMill", "published_at": "2026-06-06T00:40:15", "published_display": "06 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Compass Pathways stock being clobbered today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPck03SmxNWGZ6dHh5RGVVcUZKSjA3bFVpdTNsWHlJbFNKR0czdnhIV2UyWm56WTVBdEw1aXc5QWIwWnJBMDVSMkhSOFpGMERhVnJLS3VWQ0FOd1ZBNWpPenVya0ZCQ2F2bUR3QWFJTy1OWjJXSVRtX3hVSHlIbHhyNnFsS1h2T25BeTUzLWt3d3ZHcXRZdEpGdnBUQ2h5NEJ2Z1pNT0VUaTNZa3VLTWVtWHJzbw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is COMPASS Pathways (CMPS) Quietly Recalibrating Its Commercialization Strategy With This Board Appointment?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNWElRWjJJekplRWRRM1NFMzhvYWkyMzdudzZRMU9pa05PNEgxamZXUGpTY1RPSmVFUHVHNlpOdV9kZ3ZwNFJsejRxdlhUbERNZFF6T0xiUDdKVnhmeUlNSDJPam95eFdmRS15MGZkaUdfNTlITkw5OE1MWHM0OEN2dkp5eEpkQ0N0ZTdVcUVhTTRUY0gyRy1vcUN4SmdtTjA1U2pySnZKelhXNlNyNUpITWJn?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Board Appointment At COMPASS Pathways And What It Means For Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mental health biotech Compass Pathways taps ex-Cerevel, Sanofi exec for board", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQMy0wNlpjaHNYLWIwb2NxaklYV3d4YkVFcWs3MXZ2VU80TTRkQnY2UWliSzNLMG4zTUVwYlBJSnNGU1U2blZ3OWhMaGFVWWpleG4ycFRYMG1uOW5CUzF6c0Fqel9pdm1RRTZRUXd1YTNJYVI2bGxzNml3X1g0SWRtTHBtSkF2NzVSbkNwTWt2SEktanREcjVxN1ZtTDd6ZGVpMy1tNlg1ZnVsd3c0Znc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing COMPASS Pathways (CMPS) Valuation After Strong Q1 2026 Earnings And Key FDA Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOZ05Wd28ydGNrZ1RodHhXcTJ3SEtGUlMxQmxaMGlVdDRnbjdWQ2NpRm5rcjd4RUFJNFE2MUdSLTMwLUhFdktnaFR3UTk4Yi1SM0ZXQlNZZzlnR3AyS3I5V3BjZWdZczlCcEhyLWI0d3haZDlXOEE3UTh2RExYTEVIaDdiNjhjMXdRcTdJVUhpdzhkLV92bE5yUnFSdS1NdjlpTEhuMjh0NEFTTUVqbnpz?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "13 new Compass Pathways hires get stock awards tied to employment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQUU96YkxaY2gzN193T01hRnVTZ0RTYUpOaUZRWV9wWVBmd2dubC1JdEM1YmxZbkVSY0piMWV0ZjJyc01SWWpSUk1pYjVVUkpwd2RvZTQ2eDdXWkltbjBHd09nTTJzdFV1eDgzSW0ybEtRa1p0VURzRjZDcHY3WWR1OGFzV2ltV3V3c25majN0V2E5TGhKVW16ai1mcURpbVFqMTR2MmxxbnVnd2NjVW41ZGRpMVhsSXRhalE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies initiates Compass Pathways stock with buy on depression drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPdW5LU2I4OU1DWlNyVkNjYjcwSGlja3J5cHNQVVJPMmJIdmhRMUJlOG82bHVNRVAwZXVfZmF6aGRwNF8wa0xRSjg0LWUtbHY5cWFfWlhQZzBIa3pwNUZVb1pxQ1IxVnlZblh1QzZySWowMEtKNS1zUl9kTzAwbHlwN2p5MmhCbnRGdkJUMFBQTl95TjFLa21yVmdNeG0xdVdhbF93cDBKd3RoZlBXbm9TSHU3RklXWnNhR2x5RFdIRlRqTjF0dXBveUp3?oc=5", "source_name": "Investing.com", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has The Surge In COMPASS Pathways (CMPS) Shares Left The Valuation Looking Stretched?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNZklEcHJpR0F6V2dXSGZqUG1VUmlaTjczaldyV3Q1VEk2U1lvX21yRy1fUmlzQkdUdHdEenY2Y3hQLUJSRWkySHdUUTBSRGxkVGluUy1oYk5vMkMyQ2ljMUp4czZfSzlUY0gwZnR4UHNzUmFTRGsxSEl5cDQ4dTJ1U2YtRW1ZWENVaEc2Ry1BZnBKUFlrN0g1NnlqTDNXOW1CWGVOS2xUcnJlM0JBWU5DbTU1Q00xVUczdDJOcDdfeGFzVnRsbmFPUTQ4N2hBdXhwX2JBcV9GSk9zQlExbHp4WGttbGHSAeoBQVVfeXFMT3Q3TDFSZlV0V2RqYkVQNGdaZnF0NVVGamllOWxZaVFRUGhiWnlLZ0pydEpHTmItdGNfOVhDY0QycGN0YXFCZG5tOTFoM19LUFlVMnBabjFhWnVOMWpWd0FJaWVoQWc1ZC1qTHJLcXBfNlFSdHdsZjRESnFjVGJON2lQUEhpQllTUUo2OFlZWGtDSHBTb1hPb1plMEpseVJ2OFFELWo2Wnlla1FrSlpOV0dVUTRpbkRudklhYnpXVzgwNVBobjZOVDFnLXcyNEtET1RCbFNVQ3hCWHpOT2wwUEF1U0dpdzBsQWxn?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass' depression drug gets FDA voucher tied to 1-2 month review", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNM3JzNVJIR3hWZlM2YkhWR0VmbW05dUJqUTVsODlRZDdXVFdlQ0dRT2ZXNFNIT1FUb01GYXlGeEsxdzR1QXNoRVlsUi1GU3gxdGlsX3dtdWk0ZUphN182b3hkRFpRUW1QbW1OMVVldFMxNzZ6RGh6TjlHWHV4bzhpU1l2bjRibGhmZVdNZy1IdXNyQ0JPSjlOY3Q4cTNQZ19jdDNWX3Y5d092ZkZLR3NkeXRpY2ZIdWtta3ZnUw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes COMPASS Pathways PLC Sponsored ADR (CMPS) a Strong Momentum Stock: Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNOXBNaGJoM0s3MkFjRVFaNC1ZVW42OFlYb0hrcWMxNk90UEJTNnFVZlZaSC0wVHBwWHFrNmxkQ1ZUZzU1d2MzVmg1TElWOHgtb0tGSjZ0R2FBdWVWYjdlQzctaHZJbGZVMG9JTmwyWGU5aFN5SnBKYno3QmdZT1NUVERlSzlGaGNuWF8xVTV0UjY0eXctdWZLUG4xZElIaDdNa0Fr?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPASS Pathways Stock Rallies 50% Following Trump Executive Order on Psychedelic Research", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQeDZ2SmRtZVhPRmZXOTFTNFZxT2NNaUR2Sk5GX2p5RFFWcV9mMVoxNFBva0pORldnSkd2NXliV1NVUkZFczU5U3lsLTNmZE9UY3daWDFaODVpc1otRUVSMmRVaVNSLUtXZ3RzX3I5X3ViNFRucjVGR2pzQm4xdlM5VGxZcW5OcEV0RmxnSUZDVHhZSHZ2UGFQZGJva0JNeXZHUHVxRnJuOVJNNlM0RFhlSm9jNHJxZw?oc=5", "source_name": "TIKR.com", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways: The Bull Case Is Early, Not Wrong (NASDAQ:CMPS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPRkw3d2Z6SXpkb3JrOEdjVjdJVG1kV2hnamdGdG1VejdUeTJtT0VZLWdOMTRkOUtlTXllOEZqSlBoYUVNbkx2OE41SmIyWWtMMHlTVHZOaVByeUlJeHBuZFNWdW1BNTVBTG5TT2IwWVhMV2RCeEFCZE84aTA1a21Sd2dCTEZUWW5vZ3JxTnNnN0o5a0Za?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Psychedelic pill eases hard-to-treat depression in big Compass trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQMG9SSFBzTEdwY3c0X0dYcjYzQVlqY2pLT1hLbWFQY1ZTcXNZQV9XSzZDUzdCbnh5Mmo3T0JCUC1Bc3pua1FJcVRmRTExZG16cWhIcjd2NHJIeWdtMlJjQ1pIb2dIdzFOSVE0NzRoMkZMa01kOXRNam03dE5DZUl6M3JWRnpCVnY1WU5lendzY0JjYlpHSk5yV1k0VmxvYXNFTFhDcDNVckJITkUxVk0tSl90amVVdkxXbHVJQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPASS Pathways plc's (NASDAQ:CMPS) institutional investors lost 16% over the past week but have profited from longer-term gains", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is COMPASS Pathways (NASDAQ:CMPS) Weighed On By Its Debt Load?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Should COMP360\u2019s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T18:42:53+00:00", "published_display": "15 Jul 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is COMPASS Pathways plc (CMPS) Stock a Psychedelic Medicine Opportunity After Positive COMP360 Data?", "summary": "COMPASS Pathways plc (CMPS) is being considered a strong psychedelic medicine opportunity after positive 26-week results from its Phase 3 COMP006 study for COMP360, a treatment for resistant depression. Oppenheimer reaffirmed its Outperform rating and $20 price target, highlighti", "url": "https://uk.finance.yahoo.com/news/compass-pathways-plc-cmps-stock-092249577.html", "source_name": "Market source", "published_at": "2026-07-15T09:22:00", "published_display": "15 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dow, Nasdaq, S&P 500 Futures Climb Amid US-Iran Tensions, Fed Inflation Worries: WULF, CMPS, ANET, PENG Stocks In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQZ2o5d2J4V3JjNEpRWTVPcl90YTV3XzRleXhSYTlHS2c5NmlOelk0VnF0NDZ5R3JOQmxteEpoZEVMTzVMdVltbEg2d2xQQjAzQWNPM3kwM1I5UkhNaE9TTlpQdEVCaUIyeUV1NllTMUdHc1VWZThDZ05RSTJEeWl6aXZENUhEay1IX0FWMWxNQUNuS3pWRUgzcUQ2bjZ5b05oZHRpejJLYl9ESVdtQzc5dVlSN0Rzc3VZaHpFMWVtLVZ6bWZ4c2J4MDZJVjRlQTdXTXFhaQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T05:44:12+00:00", "published_display": "13 Jul 2026 05:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up", "summary": "", "url": "https://finance.yahoo.com/m/5ebcd5f3-d59e-32ed-a179-ee8a11921994/compass-pathways-eyes-2027.html", "source_name": "MarketBeat", "published_at": "2026-07-10T07:02:09+00:00", "published_display": "10 Jul 2026 07:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPASS Pathways (CMPS) Gets A Fresh Valuation Test On New Phase 3 Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPQXp2dy1XeE84WVJvLTlhVnJBZldGaG1jdnNpUVJ3UU00dmdrNlBKbTk5Wl93dFBKMjNZUjZaU1ZfREs0WEdUVjNmekttbUdMZ2RWaFdfd3VfekVoZWxnMlB0NDRCZ0dqX2NSYTU1ZlZrNUY3T04zUXdzSG55akdXbTVUb1RxeE1VTXZMT01vYjBJQ1lsSFM2MDZFczl0eE8zc0YzdGlDYUFVaGFSRzRpRlJFeFJFQmVidmtmbm9fTW8xNDlxbFU0YjRWSUhoMVRnY2JHNUt5Y0V4ZGxFYkZ3U3hqNF_SAeoBQVVfeXFMT0xMRkxoNFdyaElQMnl5OVpaNnltUmwtN0tHZHRsRmZkU3ZoaVNwc19oaGdBZlFaSE1KZjdqNkFGMnEzYzRoWGxpX1FXcTJPLVM0LUpabVhZOWF2bDhoczdmQmdsenVnRHdnVVNGa0gtVXV3Q2Rfb2Z3YnFnS251RWVRUHJxWDZXVVVRUEV5elVWRUpfLWZZZEpVbmhtM2lrUS1RaTZMVkxlMkgyVnJNYWkzRzc3eENFZUwxcVNnYkI1UFNpby1wdkZqZDFwV1NjSERvYkhaWm04aFZDOXV6V2ZFVnV4bHlZS0NB?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T10:35:42+00:00", "published_display": "09 Jul 2026 10:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does COMPASS Pathways (CMPS) Have Upside Left Above Fair Value?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQQjBmQUJkaGNFdFhNLWNfbUJkczJvVGp5eUhrYlE0Y3VUQjhzWkdJT25KMUJPUjUyX2NNdTlZU3hZelpDLTFxRDRuUjBnZHB5b3RXLTNORnE2SU93QkhZZXh5eVBaSDBBaVh0WVktWkxNbjEzd1FESkpCQ3Y0MURVYU92blBndzVfWFJHcnBvcFFTc3A3NTRnc3ZBRTFnOFk?oc=5", "source_name": "Market source", "published_at": "2026-07-09T02:12:00+00:00", "published_display": "09 Jul 2026 02:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOdkZXUnVmcl9lb3hlbS1DMm1vUEItNVhFbHhzclRaUUItOGFVWVNlQmdiSE81aW1IVWpmVVVuVzhWT0JvbS1VdWRWRkNhQlYxcUVQRzRTQ01pT3pjYTBienJUOVFUME5fcnhwSGdZaGJsampuNlgwLVdxZWxFcTlzZnRSNHZDSGJiR2VqYVk1ZXRuSUpvT1hwZEVwSEVkRnRqcjNIT0xjVk9nMi1LU1RjNGVZbVdaS0FFNGZhMUFvNXZPeGJFYlNWVGlQTVRBZlU?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-09T01:30:39+00:00", "published_display": "09 Jul 2026 01:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock upgraded at Evercore ISI (CMPS:NASDAQ)", "summary": "Evercore ISI has upgraded Compass Pathways (CMPS) to Outperform from Inline and significantly increased its price target to $21 from $8. This upgrade follows the release of updated late-stage trial results showcasing the long-term efficacy of the U.K.-based biotech's psychedelic ", "url": "https://seekingalpha.com/news/4612334-compass-pathways-stock-upgraded-evercore-isi", "source_name": "Seeking Alpha", "published_at": "2026-07-08T16:40:08", "published_display": "08 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of COMPASS Pathways Plc - American Depository Shares \u2013 NASDAQ:CMPS", "summary": "This page from TradingView displays the \"Price to book forward\" metric for COMPASS Pathways Plc - American Depository Shares (NASDAQ: CMPS). It indicates the stock's financial overview, specifically its price-to-book ratio on a forward-looking basis. The content provides basic co", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T03:06:12", "published_display": "08 Jul 2026 03:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways Reports Six-Month Data from Second Phase 3 Trial of Comp360 for Treatment-Resistant Depression", "summary": "Compass Pathways announced positive 26-week data from its second Phase 3 COMP006 trial for COMP360 psilocybin in treatment-resistant depression (TRD), confirming its rapid onset and durable profile. The findings, building on previous trial results, showed that 39% of patients in ", "url": "https://www.marketscreener.com/news/compass-pathways-reports-six-month-data-from-second-phase-3-trial-of-comp360-for-treatment-resistant-ce7f5ed8d88bf023", "source_name": "www.marketscreener.com", "published_at": "2026-07-08T01:40:09", "published_display": "08 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass\u2019 psilocybin shows six-month durability in Phase III trial", "summary": "Compass Pathways' psilocybin-based therapy, COMP360, has demonstrated six-month durability in a Phase III trial for treatment-resistant depression (TRD), building on earlier six-week data. The therapy showed rapid onset and sustained response, with a generally well-tolerated safe", "url": "https://www.clinicaltrialsarena.com/news/compass-psilocybin-shows-six-month-durability-in-phase-iii-trial/", "source_name": "Clinical Trials Arena", "published_at": "2026-07-08T01:39:46", "published_display": "08 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why COMPASS Pathways (CMPS) Is Down 8.2% After New Phase 3 Data and Rolling NDA Update", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T00:07:01+00:00", "published_display": "08 Jul 2026 00:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why This Psychedelics Stock Reversed Its Bearish Fortunes", "summary": "Compass Pathways (CMPS) stock saw a significant turnaround after announcing positive clinical trial results for its psilocybin-based treatment for depression. The treatment showed clinically meaningful improvements in 39% of patients after two fixed doses, with durable results la", "url": "https://www.investors.com/news/technology/compass-pathways-stock-psychedelic-drug-depression-treatment/", "source_name": "Investor's Business Daily", "published_at": "2026-07-07T20:12:43", "published_display": "07 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMP360 Psilocybin Shows Durable TRD Benefit", "summary": "Compass Pathways has announced 26-week data from its second Phase III trial of COMP360, a synthetic psilocybin formulation for treatment-resistant depression (TRD). The results indicate that antidepressant effects observed at six weeks were maintained through six months, strength", "url": "https://allsci.com/news/clinical-trials/compass-pathways-comp360-becomes-first-classic-psychedelic-to-prove-durable-six-month-benefit-in-trd/", "source_name": "AllSci", "published_at": "2026-07-07T18:11:35", "published_display": "07 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies reiterates Compass Pathways stock rating on trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOcGJmckNFUGh2LXhCTjFyZzJUVV9wWmxqLWVfVU9ESW0tcVdjanFqQXp1dGpzLWNWTUp3LS1raVYwOHBvQ05jU1ZRMFdINi1PM0ZuM0laSWFZU3U2bFVaSGxoTmtZbjBXeXJPNS1ndlNNR1ZGM1JQS2t2LXRfMFRQbjdBaVdWem5qclZhRTlsTGNoUmV1Y2VFTlRPUWJMbjA5MnNRWHlUdDNnaWFncEFEcThNeExRbmFEdGIzVjZFMmtpUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-07T15:21:25+00:00", "published_display": "07 Jul 2026 15:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile", "summary": "Compass Pathways has announced positive six-month data from its second Phase 3 trial (COMP006) for COMP360, a psilocybin treatment for treatment-resistant depression (TRD). The results reinforce the rapid onset and durable effectiveness of COMP360, showing sustained benefit up to", "url": "https://investingnews.com/compass-pathways-announces-six-month-data-from-second-phase-3-trial-confirming-rapid-and-durable-profile/", "source_name": "Investing News Network", "published_at": "2026-07-07T13:12:43", "published_display": "07 Jul 2026 13:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways Releases New Data on COMP360 for Treatment-Resistant Depression", "summary": "Compass Pathways has released new data from its Phase 3 COMP006 trial for COMP360, a treatment for resistant depression, showing rapid onset and durable clinical effects. The therapy also maintains a strong safety profile and is on track for a rolling FDA new drug application sub", "url": "https://intellectia.ai/news/stock/compass-pathways-releases-new-data-on-comp360-for-treatmentresistant-depression", "source_name": "Intellectia AI", "published_at": "2026-07-07T12:20:07", "published_display": "07 Jul 2026 12:20", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass gains on new late-stage trial data for psychedelic therapy in depression", "summary": "Compass Pathways (CMPS) saw an ~8% rise in early premarket trading after releasing new 26-week data from Part B of an ongoing late-stage trial for its psychedelic therapy, COMP360. The trial is evaluating COMP360 as a treatment for resistant depression. This positive data follows", "url": "https://seekingalpha.com/news/4611891-compass-posts-trial-data-psychedelic-drug", "source_name": "Seeking Alpha", "published_at": "2026-07-07T11:42:07", "published_display": "07 Jul 2026 11:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways says second psilocybin trial kept depression benefit for 6 months", "summary": "Compass Pathways announced 26-week results from its second Phase 3 trial (COMP006) for COMP360, a synthetic psilocybin formulation for treatment-resistant depression (TRD), confirming rapid onset and durable benefit for at least six months. This data, consistent with previous tri", "url": "https://www.stocktitan.net/news/CMPS/compass-pathways-announces-six-month-data-from-second-phase-3-trial-jkjn16eqsxqs.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:42:07", "published_display": "07 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phase 3 TRD results move Compass (NASDAQ: CMPS) toward COMP360 NDA", "summary": "Compass Pathways has reported positive 26-week data from its Phase 3 COMP006 trial for COMP360 psilocybin treatment in treatment-resistant depression (TRD), showing durable efficacy and a well-tolerated safety profile. The company is proceeding with a rolling NDA submission to th", "url": "https://www.stocktitan.net/sec-filings/CMPS/8-k-compass-pathways-plc-reports-material-event-23ad7b8f3b99.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:42:07", "published_display": "07 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways reports 6-month data from phase 3 TRD trial", "summary": "Compass Pathways announced that its COMP006 Phase 3 trial for COMP360 psilocybin in treatment-resistant depression (TRD) showed durable benefits over 26 weeks, with 39% of participants achieving significant reduction in depression scores. The company plans a rolling New Drug Appl", "url": "https://www.investing.com/news/company-news/compass-pathways-reports-6month-data-from-phase-3-trd-trial-93CH-4778700", "source_name": "Investing.com", "published_at": "2026-07-07T10:42:07", "published_display": "07 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways: COMP360 shows rapid onset, durable 26-week benefit in Phase 3 COMP006; rolling NDA on track for Q4", "summary": "Compass Pathways reported positive 26-week results for its COMP360 treatment in treatment-resistant depression from the Phase 3 COMP006 trial, showing rapid onset and durable clinical benefits. A rolling NDA submission is progressing as planned for completion in Q4 2026. The comp", "url": "https://www.tradingview.com/news/tradingview:ce91340e16419:0-compass-pathways-comp360-shows-rapid-onset-durable-26-week-benefit-in-phase-3-comp006-rolling-nda-on-track-for-q4/", "source_name": "TradingView", "published_at": "2026-07-07T10:42:07", "published_display": "07 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Compass Pathways stock gaining today? By Investing.com", "summary": "Compass Pathways Plc (CMPS) stock gained 3.5% in pre-market trading, continuing its recovery from a 52-week low. This surge is driven by anticipation for the company's COMP006 Phase 3 trial durability data, expected in early Q3 2026, and a planned New Drug Application submission ", "url": "https://m.za.investing.com/news/stock-market-news/why-is-compass-pathways-stock-gaining-today-93CH-4356023?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-06T16:40:32", "published_display": "06 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of COMPASS Pathways Plc - American Depository Shares \u2013 NASDAQ:CMPS", "summary": "This article provides price to sales forward data for COMPASS Pathways Plc (NASDAQ: CMPS). It includes the period, value, change, and percentage change. The content highlights financial data sourced from ICE Data Services and FactSet for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T23:12:28", "published_display": "05 Jul 2026 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Compass Pathways plc announced equity awards granted to eight new non-executive employees under its 2026 Inducement Plan. These grants, consisting of options and restricted share units, were made on July 1, 2026, as a material inducement for employment and are in compliance with ", "url": "https://www.businesswire.com/news/home/20260702092582/en/Compass-Pathways-Announces-New-Employee-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4", "source_name": "Business Wire", "published_at": "2026-07-02T10:30:02", "published_display": "02 Jul 2026 10:30", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways gives new hires 63,685 options and RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPbXpuR3JRbDF6WFlWVDNZQ1d0M0ZVcDY3U21oLXN0eXVSVHNjX1dXekZQbzVvdG1mU1ZTQ2EtLXJwR3pzaWxOVjA2Uk9RS1UtcGlqUHlaS2tnZFI3TlpxZG1xZ0ZUXzhfek5vaVRtanZkblBZVFRyM0U0bUhWMDRHOWRLU0tRd1JRcWNteUdjSHdNNnRwZWlHTlFtS0Vram14Z1NBWnNDbnZaY09QWEEtR0Z3QmxEQ3NmdkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways Announces FDA Granted NDA Rolling Review Request", "summary": "Compass Pathways announced that the FDA granted its NDA rolling review request for COMP360, their proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD). The company also received a Commissioner's National Priority Voucher (CNPV), which provides", "url": "https://www.natlawreview.com/press-releases/compass-pathways-announces-fda-granted-nda-rolling-review-request-and", "source_name": "The National Law Review", "published_at": "2026-07-01T23:11:46", "published_display": "01 Jul 2026 23:11", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of COMPASS Pathways Plc - American Depository Shares \u2013 NASDAQ:CMPS", "summary": "The article focuses on the enterprise value to EBIT forward metric for COMPASS Pathways Plc (NASDAQ: CMPS). It appears to be a financial data page from TradingView, providing an overview of the company's financial information within the health technology and biotechnology sectors", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPS/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:09:12", "published_display": "30 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of COMPASS Pathways Plc - American Depository Shares \u2013 NASDAQ:CMPS", "summary": "This article provides financial information for COMPASS Pathways Plc (CMPS) listed on the NASDAQ Stock Market, specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or an empty data table from TradingView, indicating that specific financia", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:41:34", "published_display": "29 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock hits 52-week high at 14.77 USD", "summary": "Compass Pathways Plc (CMPS) has hit a new 52-week high of $14.76, reflecting a robust 411% one-year stock performance and a market capitalization of $1.98 billion. This surge is attributed to investor confidence in the psychedelic therapy sector, recent positive Phase 3 data for ", "url": "https://m.uk.investing.com/news/stock-market-news/compass-pathways-stock-hits-52week-high-at-1477-usd-93CH-4746650?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-26T16:10:25", "published_display": "26 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPASS Pathways (CMPS) Receives a Buy from H.C. Wainwright", "summary": "H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on COMPASS Pathways (CMPS) with a price target of $70.00. Trucchio, a 5-star analyst, has a strong track record in the Healthcare sector. The company recently reported a significant net profit of $91.05 million for ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/16053/compass-pathways-cmps-receives-a-buy-from-h-c-wainwright/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T13:10:25", "published_display": "26 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPASS Pathways Plc Sponsored ADR Actuals & Estimates (NASDAQ:CMPS)", "summary": "This article provides an overview of COMPASS Pathways Plc (NASDAQ: CMPS) on TradingView, focusing on its financial actuals and estimates. It highlights reported financial data and analyst estimates across various financial statements and valuation metrics, allowing users to compa", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPS/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-25T23:09:54", "published_display": "25 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways PLC (CMPS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Compass Pathways PLC (CMPS) stock, focusing on its dividend and stock split history. It states that no dividends have been distributed over the past five years and no stock split data is available. The article also includes current stock price", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmps/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T12:40:34", "published_display": "18 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways PLC (CMPS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Compass Pathways PLC (CMPS), including analyst ratings, target prices, and EPS estimates. Based on 16 analysts, the stock has a \"Buy\" rating with an average target price of $21.719, representing an 89.02% upside. The report also high", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmps/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T07:40:34", "published_display": "18 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways PLC (CMPS) Institutional Confidence", "summary": "This article provides an overview of Compass Pathways PLC (CMPS) focusing on its institutional confidence, a component of its TradingKey Stock Score. It details institutional shareholdings and recent activity by significant investors, including changes in their positions. Key ins", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmps/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:34", "published_display": "18 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways IPO to Begin Trading 18th September on Nasdaq: CMPS", "summary": "Compass Pathways has announced that its initial public offering of 7.5 million shares will begin trading on the Nasdaq Global Select Market today, September 18, 2020, under the ticker CMPS. The shares are priced at $17.00, raising gross proceeds of $127.5 million. The offering is", "url": "https://psychedelicalpha.com/news/compass-pathways-ipo-to-begin-trading-18th-september-on-nasdaq-cmps/", "source_name": "Psychedelic Alpha", "published_at": "2026-06-16T03:40:11", "published_display": "16 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is COMPASS Pathways plc (CMPS) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxON3BoZXYtVloyYXVJMHA0amx2TFNJT2JXVU9FS1pIQThER0lqZXFIS0htMTFGUFp5eHc1alc4ZVowOXZLU09hMVNfOUJkajRzWlhud1hZX2dveHJWaEJQSVluXzZBYzhTbXo0SUpTdlZadUdieHdxdTY0TlR4NEhab2NIVVI0cFRlS1ZfLVBXYjkwM0h6ZEl1YWZWdw?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript: Compass Pathways Q1 2026 Earnings Conference Call", "summary": "Compass Pathways reported positive data from its Phase 3 studies of COM360 for treatment-resistant depression (TRD), showing rapid and durable efficacy. The company is preparing for a potential accelerated launch by the end of the year, backed by strong financials, ongoing FDA co", "url": "https://finance.yahoo.com/sectors/healthcare/articles/transcript-compass-pathways-q1-2026-223421373.html", "source_name": "Market source", "published_at": "2026-06-06T12:41:33", "published_display": "06 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPS Stock Chart | COMPASS PATHWAYS PLC (NASDAQ:CMPS)", "summary": "This article provides a stock chart for COMPASS PATHWAYS PLC (NASDAQ:CMPS) on ChartMill.com. It displays the current stock price, daily changes, and after-hours trading information. The page also offers various trading tools and market data for analysis.", "url": "https://www.chartmill.com/stock/quote/CMPS/stock-chart", "source_name": "ChartMill", "published_at": "2026-06-06T00:40:15", "published_display": "06 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Compass Pathways stock being clobbered today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPck03SmxNWGZ6dHh5RGVVcUZKSjA3bFVpdTNsWHlJbFNKR0czdnhIV2UyWm56WTVBdEw1aXc5QWIwWnJBMDVSMkhSOFpGMERhVnJLS3VWQ0FOd1ZBNWpPenVya0ZCQ2F2bUR3QWFJTy1OWjJXSVRtX3hVSHlIbHhyNnFsS1h2T25BeTUzLWt3d3ZHcXRZdEpGdnBUQ2h5NEJ2Z1pNT0VUaTNZa3VLTWVtWHJzbw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is COMPASS Pathways (CMPS) Quietly Recalibrating Its Commercialization Strategy With This Board Appointment?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNWElRWjJJekplRWRRM1NFMzhvYWkyMzdudzZRMU9pa05PNEgxamZXUGpTY1RPSmVFUHVHNlpOdV9kZ3ZwNFJsejRxdlhUbERNZFF6T0xiUDdKVnhmeUlNSDJPam95eFdmRS15MGZkaUdfNTlITkw5OE1MWHM0OEN2dkp5eEpkQ0N0ZTdVcUVhTTRUY0gyRy1vcUN4SmdtTjA1U2pySnZKelhXNlNyNUpITWJn?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Board Appointment At COMPASS Pathways And What It Means For Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mental health biotech Compass Pathways taps ex-Cerevel, Sanofi exec for board", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQMy0wNlpjaHNYLWIwb2NxaklYV3d4YkVFcWs3MXZ2VU80TTRkQnY2UWliSzNLMG4zTUVwYlBJSnNGU1U2blZ3OWhMaGFVWWpleG4ycFRYMG1uOW5CUzF6c0Fqel9pdm1RRTZRUXd1YTNJYVI2bGxzNml3X1g0SWRtTHBtSkF2NzVSbkNwTWt2SEktanREcjVxN1ZtTDd6ZGVpMy1tNlg1ZnVsd3c0Znc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing COMPASS Pathways (CMPS) Valuation After Strong Q1 2026 Earnings And Key FDA Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOZ05Wd28ydGNrZ1RodHhXcTJ3SEtGUlMxQmxaMGlVdDRnbjdWQ2NpRm5rcjd4RUFJNFE2MUdSLTMwLUhFdktnaFR3UTk4Yi1SM0ZXQlNZZzlnR3AyS3I5V3BjZWdZczlCcEhyLWI0d3haZDlXOEE3UTh2RExYTEVIaDdiNjhjMXdRcTdJVUhpdzhkLV92bE5yUnFSdS1NdjlpTEhuMjh0NEFTTUVqbnpz?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "13 new Compass Pathways hires get stock awards tied to employment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQUU96YkxaY2gzN193T01hRnVTZ0RTYUpOaUZRWV9wWVBmd2dubC1JdEM1YmxZbkVSY0piMWV0ZjJyc01SWWpSUk1pYjVVUkpwd2RvZTQ2eDdXWkltbjBHd09nTTJzdFV1eDgzSW0ybEtRa1p0VURzRjZDcHY3WWR1OGFzV2ltV3V3c25majN0V2E5TGhKVW16ai1mcURpbVFqMTR2MmxxbnVnd2NjVW41ZGRpMVhsSXRhalE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies initiates Compass Pathways stock with buy on depression drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPdW5LU2I4OU1DWlNyVkNjYjcwSGlja3J5cHNQVVJPMmJIdmhRMUJlOG82bHVNRVAwZXVfZmF6aGRwNF8wa0xRSjg0LWUtbHY5cWFfWlhQZzBIa3pwNUZVb1pxQ1IxVnlZblh1QzZySWowMEtKNS1zUl9kTzAwbHlwN2p5MmhCbnRGdkJUMFBQTl95TjFLa21yVmdNeG0xdVdhbF93cDBKd3RoZlBXbm9TSHU3RklXWnNhR2x5RFdIRlRqTjF0dXBveUp3?oc=5", "source_name": "Investing.com", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has The Surge In COMPASS Pathways (CMPS) Shares Left The Valuation Looking Stretched?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass' depression drug gets FDA voucher tied to 1-2 month review", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNM3JzNVJIR3hWZlM2YkhWR0VmbW05dUJqUTVsODlRZDdXVFdlQ0dRT2ZXNFNIT1FUb01GYXlGeEsxdzR1QXNoRVlsUi1GU3gxdGlsX3dtdWk0ZUphN182b3hkRFpRUW1QbW1OMVVldFMxNzZ6RGh6TjlHWHV4bzhpU1l2bjRibGhmZVdNZy1IdXNyQ0JPSjlOY3Q4cTNQZ19jdDNWX3Y5d092ZkZLR3NkeXRpY2ZIdWtta3ZnUw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes COMPASS Pathways PLC Sponsored ADR (CMPS) a Strong Momentum Stock: Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNOXBNaGJoM0s3MkFjRVFaNC1ZVW42OFlYb0hrcWMxNk90UEJTNnFVZlZaSC0wVHBwWHFrNmxkQ1ZUZzU1d2MzVmg1TElWOHgtb0tGSjZ0R2FBdWVWYjdlQzctaHZJbGZVMG9JTmwyWGU5aFN5SnBKYno3QmdZT1NUVERlSzlGaGNuWF8xVTV0UjY0eXctdWZLUG4xZElIaDdNa0Fr?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPASS Pathways Stock Rallies 50% Following Trump Executive Order on Psychedelic Research", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQeDZ2SmRtZVhPRmZXOTFTNFZxT2NNaUR2Sk5GX2p5RFFWcV9mMVoxNFBva0pORldnSkd2NXliV1NVUkZFczU5U3lsLTNmZE9UY3daWDFaODVpc1otRUVSMmRVaVNSLUtXZ3RzX3I5X3ViNFRucjVGR2pzQm4xdlM5VGxZcW5OcEV0RmxnSUZDVHhZSHZ2UGFQZGJva0JNeXZHUHVxRnJuOVJNNlM0RFhlSm9jNHJxZw?oc=5", "source_name": "TIKR.com", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways: The Bull Case Is Early, Not Wrong (NASDAQ:CMPS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPRkw3d2Z6SXpkb3JrOEdjVjdJVG1kV2hnamdGdG1VejdUeTJtT0VZLWdOMTRkOUtlTXllOEZqSlBoYUVNbkx2OE41SmIyWWtMMHlTVHZOaVByeUlJeHBuZFNWdW1BNTVBTG5TT2IwWVhMV2RCeEFCZE84aTA1a21Sd2dCTEZUWW5vZ3JxTnNnN0o5a0Za?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Psychedelic pill eases hard-to-treat depression in big Compass trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQMG9SSFBzTEdwY3c0X0dYcjYzQVlqY2pLT1hLbWFQY1ZTcXNZQV9XSzZDUzdCbnh5Mmo3T0JCUC1Bc3pua1FJcVRmRTExZG16cWhIcjd2NHJIeWdtMlJjQ1pIb2dIdzFOSVE0NzRoMkZMa01kOXRNam03dE5DZUl6M3JWRnpCVnY1WU5lendzY0JjYlpHSk5yV1k0VmxvYXNFTFhDcDNVckJITkUxVk0tSl90amVVdkxXbHVJQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPASS Pathways plc's (NASDAQ:CMPS) institutional investors lost 16% over the past week but have profited from longer-term gains", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is COMPASS Pathways (NASDAQ:CMPS) Weighed On By Its Debt Load?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 106, "total_relevant": 54, "sentiment_summary": {"positive": 27, "negative": 0, "neutral": 27, "score": 63, "total": 54, "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 19.4, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 12}, {"event": "analyst", "label": "Analyst action", "weight": 3.1, "count": 5}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 27, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 13.64, "latest_week": "2026-07-10", "one_week_move": 0.1, "four_week_move": 12.9, "twelve_week_move": 104.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.185238, "market_dynamics_buy_signal": false, "relative_strength": 65.644017, "fair_value_gap": 102.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 43.8929, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.1% over one week, +12.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": ["Sentiment confirms active trend", "Positive but stretched"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": ["Constructive tone is arriving with price materially above fair value."], "event_label": "Market update", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "simplywall.st", "count": 7}, {"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "Investing.com", "count": 5}, {"label": "Seeking Alpha", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "Stocktwits", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 12}, {"label": "Analyst action", "count": 5}, {"label": "Macro sensitivity", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "63/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "positive", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.1% over one week, +12.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Should COMP360\u2019s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors?"}], "updated_at": "2026-07-16T03:02:22.194988+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}